πŸ‡ΊπŸ‡Έ FDA
Patent

US 11472772

S1P3 antagonists

granted A61PA61P29/00

Quick answer

US patent 11472772 (S1P3 antagonists) held by TEVA PHARMACEUTICAL INDUSTRIES, LTD. expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Grant date
Tue Oct 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61P, A61P29/00